TLS Advisors LLC Lowers Stock Holdings in Xenon Pharmaceuticals Inc. $XENE

TLS Advisors LLC decreased its holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) by 42.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 18,858 shares of the biopharmaceutical company’s stock after selling 14,098 shares during the period. Xenon Pharmaceuticals accounts for about 1.5% of TLS Advisors LLC’s portfolio, making the stock its 11th biggest holding. TLS Advisors LLC’s holdings in Xenon Pharmaceuticals were worth $845,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the business. Arizona State Retirement System grew its position in shares of Xenon Pharmaceuticals by 1.8% during the third quarter. Arizona State Retirement System now owns 19,290 shares of the biopharmaceutical company’s stock worth $774,000 after purchasing an additional 334 shares in the last quarter. Quarry LP boosted its holdings in shares of Xenon Pharmaceuticals by 25.0% in the 3rd quarter. Quarry LP now owns 2,500 shares of the biopharmaceutical company’s stock worth $100,000 after purchasing an additional 500 shares during the period. Altfest L J & Co. Inc. lifted its stake in shares of Xenon Pharmaceuticals by 6.5% during the 4th quarter. Altfest L J & Co. Inc. now owns 8,232 shares of the biopharmaceutical company’s stock worth $369,000 after acquiring an additional 501 shares during the last quarter. State of Wyoming lifted its stake in shares of Xenon Pharmaceuticals by 112.8% during the 3rd quarter. State of Wyoming now owns 1,151 shares of the biopharmaceutical company’s stock worth $46,000 after acquiring an additional 610 shares during the last quarter. Finally, Blue Trust Inc. raised its position in Xenon Pharmaceuticals by 2,560.7% during the 4th quarter. Blue Trust Inc. now owns 745 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 717 shares in the last quarter. Hedge funds and other institutional investors own 95.45% of the company’s stock.

Insiders Place Their Bets

In other Xenon Pharmaceuticals news, insider Christopher John Kenney sold 2,771 shares of the business’s stock in a transaction that occurred on Tuesday, March 10th. The stock was sold at an average price of $60.11, for a total transaction of $166,564.81. Following the transaction, the insider owned 4,729 shares in the company, valued at approximately $284,260.19. The trade was a 36.95% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Andrea Difabio sold 2,607 shares of the business’s stock in a transaction that occurred on Tuesday, March 10th. The stock was sold at an average price of $60.11, for a total value of $156,706.77. Following the transaction, the insider owned 4,893 shares in the company, valued at $294,118.23. The trade was a 34.76% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 296,707 shares of company stock worth $17,845,365. Company insiders own 4.07% of the company’s stock.

Xenon Pharmaceuticals Stock Performance

XENE opened at $55.00 on Wednesday. The business’s 50-day simple moving average is $55.33 and its 200-day simple moving average is $46.89. Xenon Pharmaceuticals Inc. has a one year low of $28.19 and a one year high of $63.95. The stock has a market capitalization of $5.32 billion, a P/E ratio of -11.70 and a beta of 0.65.

Xenon Pharmaceuticals (NASDAQ:XENE) last issued its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($1.17) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($1.17). During the same period last year, the firm posted ($0.83) earnings per share. On average, equities research analysts forecast that Xenon Pharmaceuticals Inc. will post -4.87 EPS for the current fiscal year.

Key Stories Impacting Xenon Pharmaceuticals

Here are the key news stories impacting Xenon Pharmaceuticals this week:

• Positive Sentiment: JPMorgan Chase & Co. raised its price target on Xenon Pharmaceuticals to $80 from $77 and reiterated an Overweight rating, implying significant upside from the current share price. Benzinga article
• Positive Sentiment: HC Wainwright lifted earnings estimates across multiple periods, including FY2026, FY2027, FY2028, FY2029, and FY2030, while maintaining a Buy rating and a $74 price target, signaling improved long-term expectations for Xenon.
• Positive Sentiment: Recent headlines referenced positive X-TOLE2 phase 3 data and an extended cash runway, which may support the company’s valuation and reduce financing concerns. Yahoo Finance article
• Neutral Sentiment: HC Wainwright also adjusted near-term quarterly EPS estimates higher for Q2, Q3, and Q4 2026, though Xenon is still expected to post losses, so the impact is more about improving outlook than near-term profitability.
• Neutral Sentiment: Short interest data showed no meaningful update, with reported short interest at zero shares, offering little signal for trading sentiment.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on XENE shares. Wells Fargo & Company reissued an “overweight” rating and issued a $69.00 price target on shares of Xenon Pharmaceuticals in a research report on Sunday. Deutsche Bank Aktiengesellschaft boosted their price objective on Xenon Pharmaceuticals from $56.00 to $90.00 and gave the company a “buy” rating in a report on Tuesday, March 10th. Morgan Stanley set a $97.00 target price on Xenon Pharmaceuticals in a report on Monday, March 9th. Stifel Nicolaus set a $66.00 price target on Xenon Pharmaceuticals in a research report on Tuesday, February 10th. Finally, Wolfe Research assumed coverage on Xenon Pharmaceuticals in a research report on Monday, February 23rd. They issued an “outperform” rating and a $60.00 price objective for the company. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Xenon Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $75.69.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.